Hydroxicloroquine for Pre-Exposure Prophylaxis for SARS-COV-2
Jaime López De La Iglesia, Naiara Cubelos Fernández, Roi Naveiro Flores, Marina Montoro Gómez, Francisco Javier González De Haro, María Ajenjo González, Estefanía Tobal Vicente, María Lamuedra Gil De Gómez, María Teresa Nuevo Guisado, Isabel Torio Gómez, Ana Peñalver Andrada, Nuria Martínez Cao, Paula González Figaredo, Carlos Robles García, Lidia Anastasia Alvarado Machón, Ángeles Lafont Alcalde, José Cesáreo Naveiro Rilo
doi:10.1101/2020.08.31.20185314
SARS-CoV-2 infection has a high transmission level. At the present time there is not a specific treatment approved but it is known that, in vitro, chloroquine and hydroxychloroquine can inhibit the coronavirus. Objective: verifying if patients with autoimmune diseases that are on treatment with HCQ have less incidence and severity on COVID-19. Material and methods: this is a retrospective cohort study. The exposed cohort was formed by individuals with autoimmune diseases with HCQ treatment. The control cohort was randomly selected using the Health Card database. To deal with confounding variables and evaluate the effect of HCQ on the incidence and severity of SARS-CoV-2 infection, propensity score matching was used. Risk difference and paired percentage difference between exposed and non-exposed groups was estimated. Results: 919 individuals formed the exposed cohort and 1351 the control cohort. After matching, there were 690 patients on each group. During the time of the study, in the exposed group there were 42 (6.1%) individuals with suspected COVID-19, 12(1.7%) with confirmed COVID-19 and 3(0.4%) were hospitalized. In the control group there were 30(4.3%) individuals with suspected COVID-19, 13(1.9%) with confirmed COVID-19 and 2(0.3%) were hospitalized. The risk difference between each cohort was: 0.017(-0.05-0.04) for suspected COVID-19; -0.014(-0.015-0.012) for confirmed COVID-19 and 0.001(-0.007-0.007) for hospitalized patients. There were not significant differences.
Conclusion: there is no difference neither on the incidence nor on the severity of COVID-19 between patients with autoimmune diseases with HCQ treatment and patients that do not take HCQ.
References
Ajenjo, None
Al-Kofaji, Jabobson, Boulware, Matas, Kandaswamy et al., Finding the Dos for Hydroxychloroquine Prophylaxis for COVID-19: The Desperate Search for Effectiveness, Clinical Pharmacology & Therapeutics,
doi:10.1002/cpt.1874Anastasia, Machón, None
Becker, Ichino, Estimation of average treatment effects based on propensity scores, The Stata journal
Biot, Daher, Chavain, Design and synthesis of hydroxyferroquine derivatives with antimalarial and antiviral activities, J Med Chem,
doi:10.1021/jm0601856Brady, Remarks by President Trump, Vice President Pence, and Members of the Coronavirus Task Force in Press Briefing
Buuren, Groothuis-Oudshoorn, Mice: Multivariate imputation by chained equations in R, Journal of statistical software
Buuren, Groothuis-Oudshoorn, Mice: Multivariate imputation by chained equations in R, Journal of statistical software
Cavalcanti, Zampieri, Regis, Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19, NEJM,
doi:10.1056/NEJMoa2019014Chen, Hu, Zhang, Jiang, Han et al., Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial,
doi:10.1101/2020.03.22.20040758Chen, Hu, Zhang, Jiang, Han et al., Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial, Epidemiology,
doi:10.1101/2020.03.22.20040758Cubelos, None
Cummings, Baldwin, Abrams, Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study
Francisco, Haro, None
Gautret, Lagier, Parola, Hoang, Meddeb et al., Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, Int J Antimicrob Agents,
doi:10.1016/j.ijantimicag.2020.105949Gianfrancesco, Hyrich, Al-Adelys, Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID 19 Global Rheumatology Alliance physician-reported registry
González, None
Konig, Kim, Scheetz, Graef, Liew et al., Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19, Annals of the Rheumatic Diseases,
doi:10.1136/annrheumdis-2020-217690Lamuedra, De, None
Lee, Son, Peck, Can post-exposure prophylaxis for COVID-19 be considered as an outbreak response strategy in long-term care hospitals?, Int J Antimicrob Agents,
doi:10.1016/j.ijantimicag.2020.105988López, de la Iglesia 1
Mahévas, Tran, Roumier, Chabrol, Paule et al., Clinical efficacy of hydroxychloroquine in patients with COVID-19 pneumonia who require oxygen: observational comparative study using routine care data, BMJ,
doi:10.1136/bmj.m1844Martínez, None
Mathian, Mahevas, Rohmer, Roumier, Cohen-Aubart et al., Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine, Ann Rheum Dis,
doi:10.1136/annrheumdis-2020-217566Mehra, Desai, Td, Patel, Cardiovascular Disease, Drug Therapy, and Mortality in COVID-19 (published on line, N Engl J Med
Million, Lagier, Gautret, Colson, Fournier et al., Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France, Travel Med Infect Dis,
doi:10.1016/j.tmaid.2020.101Montoro, None
Pablos, Abasolo-Alcázar, Álvaro-Gracia, Blanco, Prevalence of hospital PCR confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases, Ann Rheum Dis,
doi:10.1101/2020.05Pablos, Galindo, Carmona, Retuerto, Lledó et al., Clinical Outcomes of Patients with COVID-19 and Chronic Inflammatory and Autoimmune Rheumatic Diseases: A Multicentric Matched-Cohort Study,
doi:10.1101/2020.06.18.20133645Peñalver, None
Robles, None
Roi, Flores, None
Rosenbaum, Rubin, The central role of the propensity score in observational studies for causal effects, Biometrika
Rosenberg, Dufort, Udo, Wilberschied, Kumar et al., Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State, JAMA,
doi:10.1001/jama.2020.8630Savarino, Boelaert, Cassone, Majori, Cauda, Effects of chloroquine on viral infections: an old drug against today's diseases?, Lancet Infect Dis
Sekhon, Multivariate and propensity score matching software with automated balance optimization: the matching package for R, Journal of Statistical Software,
doi:10.18637/jss.v042.i07Shah, Das, Jain, Misra, Negi, A systematic review of the prophylactic role of chloroquine and hydroxychloroquine in coronavirus disease-19 (COVID-19), Int J Rheum Dis,
doi:10.1111/1756-185X.13842Silva, Boyd, Wallwork, Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US 'hot spot
Tang, Cao, Han, Wang, Chen et al., Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial, BMJ,
doi:10.1136/bmj.m1849Teresa, Guisado, None
Tobal, None
Torio, None
Villa, Mandell, Trastornos cardiovasculares y enfermedad reumatica, Rev Esp Cardiol
Yaox, Zhang, Cui, Huang, Niu, In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome main point: hydroxychloroquine was found to be more potent than chloroquine at inhibiting SARS-CoV-2 in vit, Clin Infect Dis
Zhou, Yu, Du, Clinical course and risk factors for mortality of adult In patients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet
